Digital technologies in prostate cancer prevention and early diagnosis

Abstract

Background. Prostate cancer is one of the most common malignant neoplasms in males. The Russian Federation observed the same patterns: the incidence of prostate cancer is steadily growing, without the tendency to decrease. Currently, no effective methods are available for prostate cancer early diagnosis and screening.

Aim. To improve the effectiveness of prostate cancer prevention and early diagnosis with new digital technologies for high-risk cancer group formation

Material and methods. Data from the Cancer Registry population in the “Altai regional cancer center,” Barnaul City was used. The Cancer Registry includes information about 253,000 patients with malignant neoplasms, including 14,482 males suffering from prostate cancer. Based on the targeted prevention method of A.F. Lazarev, “Method for determining the risk of prostate cancer” (Patent 2692987) and “Automated program for early diagnosis of prostate cancer” (certificate of state registration of the computer program No. 2019663514) was developed, which simplifies the stage of forming groups of precancerous high oncorisk and increases prostate cancer detection, as well as develops personalized targeted preventive measures for each patient.

Results. The study formed a group of 328 patients with precancerous high oncorisk for prostate cancer in the Cancer Registry, wherein an in-depth examination revealed 26 patients with prostate cancer, which was 7.9%. Stages I and II were established in 97.8%.

Conclusion. The web application “Automated program for early diagnosis of prostate cancer” allows the group formation of high-risk patients who are a targeted search for prostate cancer. The testing process allows a large number of patients to be examined in a short time. The “automated program for the early diagnosis of prostate cancer” allows a statistically significant increased prostate cancer detection, as well as personalized preventive measure suggestions for each patient.

Keywords

prostate cancer / digital technologies / prevention and early diagnosis

References

[1] Seer.cancer.gov [Intrenet]. Surveillance, Epidemiology, and End Rezults Program. Prostate cancer. National Cancer Institute [cited 2021 Oct 1]. Available from: http://www.seer.cancer.gov.

[2] Seer.cancer.gov [Intrenet]. Surveillance, Epidemiology, and End Rezults Program. Prostate cancer. National Cancer Institute [дата обращения: 1.10.2021]. Доступ по ссылке: http://www.seer.cancer.gov.

[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492

[4] Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2018. Vol. 68, N 6. P. 394-424. doi: 10.3322/caac.21492

[5] World Health Organisation [Internet]. World Source: Globocan 2018 [cited 2021 Oct 1]. Available from: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.

[6] World Health Organisation [Internet]. World Source: Globocan 2018 [дата обращения: 1.10.2021]. Доступ по ссылке: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.

[7] Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen – branch FGBI «NERC» Ministry of health of Russia; 2020. (In Russ).

[8] Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.

[9] Kaprin AD, Starinsky VV, Shakhzadova AO. The state of cancer care in Russia in 2020. Moscow: MNIOI im. P.A. Herzen – branch FGBI «NERC» Ministry of health of Russia; 2021. (In Russ).

[10] Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2020 году М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021.

[11] Sergeeva NS, Skachkova TE, Marshutina NV et al. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. P.A. Herzen journal of oncology. 2018; 7(1):55-67. (In Russ). doi: 10.17116/onkolog20187155-67

[12] Сергеева Н.С., Скачкова Т.Е., Маршутина Н.В., и др. Клиническая значимость ПСА-ассоциированных тестов в диагностике и стадировании рака предстательной железы // Онкология. Журнал им. П.А. Герцена. 2018. Т. 7, № 1. С. 55-67. doi: 10.17116/onkolog20187155-67

[13] Pushkar’ DY, Rasner PI. Differential diagnosis of cancer and benign prostatic hyperplasia. Russkii meditsinskii zhurnal. 2014;22(17):1298-1303. (In Russ).

[14] Пушкарь Д.Ю., Раснер П.И. Дифференциальная диагностика рака и доброкачественной гиперплазии предстательной железы // Русский медицинский журнал. 2014. Т 22, №17. С. 1298-1303.

[15] Assotsiatsiya onkologov Rossii. Prostate cancer. Clinical recommendations. Moscow; 2020. 140 p. (In Russ).

[16] Ассоциация онкологов России. Рак предстательной железы. Клинические рекомендации. М.; 2020. 140 с.

[17] Lazarev AF. Territorial Cancer Registry. Certificate of state registration of a computer program (2008611703). March 31, 2008. (20088610743).Feb 26, 2008. Federal Service for Intellectual Property, patents and trademarks. (In Russ).

[18] Свидетельство о государственной регистрации программы для ЭВМ №2008611703, 31.03.2008 г. Лазарев А.Ф. Территориальный раковый регистр. Заявка №2008610743.

[19] Lazarev AF, Lazarev SA, editors. Formation of cancer risk groups using digital technologies: guidelines for doctors, residents and students. Barnaul: AGMU – branch FGBI «AGMU» Ministry of health of Russia; 2020. (In Russ).

[20] Лазарев А.Ф. Формирование групп онкологического риска с использованием цифровых технологий: методические рекомендации для врачей, ординаторов и студентов / под ред. А.Ф. Лазарева. Барнаул: Изд-во ФГБОУ ВО АГМУ Минзрава России, 2020.

[21] Patent RUS №2692987/ 28.06.2019. Lazarev AF. Method for determining the risk of prostate cancer. Available from: https://patenton.ru/patent/RU2692987C1. (In Russ).

[22] Патент РФ на изобретение № 2692987/ 28.06.19. Лазарев А.Ф. Способ определения риска рака предстательной железы. Режим доступа: https://patenton.ru/patent/RU2692987C1. Дата обращения: 01.10.2021.

[23] Russian Certificate of state registration of a computer program N 2019663514, 17.10.2019. Lazarev AF, Pokornyak VP, Marchkov VA, Lazarev SA, Petrova VD. Automated program for early diagnosis of prostate cancer (prostate cancer). Application no.2019662379.

[24] Свидетельство о государственной регистрации программы для ЭВМ № 2019663514, 17.10.2019 г. Лазарев А.Ф., Покорняк В.П., Марчков В.А., Лазарев С.А., Петрова В.Д. Автоматизированная программа ранней диагностики рака предстательной железы (РПЖ). Заявка № 2019662379.

RIGHTS & PERMISSIONS

Eco-Vector